Carregant...
Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
BACKGROUND: The present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A(1c) (HbA(1c)) levels, and corrected QT interval (QTc) prolongation] associated with the use of blonanserin and perospirone...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3913743/ https://ncbi.nlm.nih.gov/pubmed/24505373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0088049 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|